Clinical Trial Patient Records
This dataset provides comprehensive, subject-level records from simulated clinical trials, including patient demographics, treatment assignments, progress tracking, and outcome measures. It supports robust biostatistical analyses and machine learning applications for clinical research, safety monitoring, and predictive modeling of trial outcomes.
Sample rows
preview · 8 of 203 rows · all 20 columns| patient_idstring | outcome_summarystring | primary_outcome_valuefloat | serious_adverse_eventboolean | race_ethnicitystring | trial_idstring | site_idstring | enrollment_datedate | ageinteger | sexstring | treatment_groupstring | randomization_datedate | baseline_measurementsstring | visit_numberinteger | last_visit_datedate | progress_statusstring | primary_outcome_datedate | adverse_events_reportedinteger | withdrawal_reasonstring | death_datedate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PT-TRIAL1-001 | improved | 2.3 | false | White | TRIAL-2023A | SITE-NY-101 | 2022-01-12 | 42 | female | drug A | 2022-01-13 | BP:120/76, Wt:71kg, Chol:181, LDL:102 | 7 | 2022-07-19 | completed | 2022-07-19 | 1 | blank | blank |
| P-TR2-CA-21 | improved | 1.2 | false | Asian | TRIAL-2023B | SITE-CA-203 | 2022-02-04 | 35 | male | drug B | 2022-02-05 | BP:128/80, Wt:65kg, Glu:89, ALT:36 | 6 | 2022-08-10 | completed | 2022-08-10 | 0 | blank | blank |
| P3-TRIAL1-113 | unchanged | 0.7 | false | Black/African American | TRIAL-2023A | SITE-WA-305 | 2022-03-09 | 58 | female | drug C | 2022-03-11 | BP:132/85, Wt:89kg, HbA1c:6.1 | 8 | 2022-09-08 | completed | 2022-09-08 | 2 | blank | blank |
| PAT-TRIAL3-900 | worsened | -0.2 | false | Native American | TRIAL-2024A | SITE-TX-409 | 2022-05-21 | 67 | male | placebo | 2022-05-22 | BP:145/88, Wt:95kg, eGFR:87 | 10 | 2023-01-10 | completed | 2023-01-10 | 3 | blank | blank |
| PT-TRIAL4-002 | improved | 1.5 | false | Hispanic/Latino | TRIAL-2024B | SITE-IL-512 | 2022-06-01 | 31 | female | drug B | 2022-06-03 | BP:119/76, Wt:62kg, Chol:159 | 6 | 2022-12-12 | completed | 2022-12-12 | 1 | blank | blank |
| PT-TRIAL2-003 | improved | 2.7 | false | White | TRIAL-2023C | SITE-FL-615 | 2022-04-02 | 49 | male | drug A | 2022-04-04 | BP:124/82, Wt:77kg, LDL:95, HbA1c:5.7 | 9 | 2022-11-30 | completed | 2022-11-30 | 0 | blank | blank |
| PT-TRIAL3-011 | improved | 1.8 | false | Asian | TRIAL-2023B | SITE-TX-419 | 2022-06-15 | 36 | female | drug C | 2022-06-16 | BP:117/75, Wt:54kg, Chol:145 | 7 | 2022-12-20 | completed | 2022-12-20 | 1 | blank | blank |
| PT-TRIAL5-018 | unchanged | 0.9 | false | Other | TRIAL-2024B | SITE-NY-127 | 2023-01-09 | 62 | male | placebo | 2023-01-11 | BP:137/88, Wt:84kg, Glu:103 | 8 | 2023-07-02 | completed | 2023-07-02 | 2 | blank | blank |
| P-TRIAL2-021 | worsened | -0.6 | true | Asian | TRIAL-2023D | SITE-PA-333 | 2022-09-22 | 77 | male | drug B | 2022-09-23 | BP:145/90, Wt:90kg, eGFR:64 | 12 | 2023-03-12 | completed | 2023-03-12 | 4 | blank | blank |
| P5-TRIAL1-002 | improved | 2.5 | false | White | TRIAL-2023A | SITE-CA-211 | 2022-06-11 | 27 | female | drug C | 2022-06-12 | BP:110/68, Wt:57kg, Glu:81, Chol:135 | 6 | 2022-12-18 | completed | 2022-12-18 | 0 | blank | blank |
| P6-TRIAL2-010 | unchanged | 0.8 | false | White | TRIAL-2023D | SITE-FL-625 | 2022-07-19 | 54 | male | drug B | 2022-07-20 | BP:120/83, Wt:81kg, Chol:188, LDL:102 | 7 | 2023-01-25 | completed | 2023-01-25 | 2 | blank | blank |
| PT-TR3-MT-01 | improved | 1.3 | false | Hispanic/Latino | TRIAL-2024A | SITE-MT-511 | 2022-02-12 | 62 | female | drug C | 2022-02-13 | BP:130/84, Wt:80kg, CRP:4.7 | 10 | 2022-09-02 | completed | 2022-09-02 | 2 | blank | blank |
| P8-TRIAL2-303 | unchanged | 0.2 | false | Asian | TRIAL-2023C | SITE-WA-315 | 2022-08-15 | 39 | male | placebo | 2022-08-16 | BP:119/70, Wt:65kg, ALT:40 | 7 | 2023-02-14 | completed | 2023-02-14 | 0 | blank | blank |
| PT-TRIAL1-015 | improved | 2.8 | false | White | TRIAL-2023A | SITE-NY-105 | 2022-10-12 | 24 | female | drug B | 2022-10-13 | BP:112/73, Wt:54kg, Chol:146 | 6 | 2023-04-09 | completed | 2023-04-09 | 1 | blank | blank |
| P9-TRIAL4-040 | improved | 1.9 | false | Black/African American | TRIAL-2024A | SITE-VA-814 | 2022-07-10 | 49 | other | drug C | 2022-07-12 | BP:127/80, Wt:68kg, HbA1c:5.9 | 7 | 2023-01-11 | completed | 2023-01-11 | 1 | blank | blank |
| PT-TRIAL2-101 | worsened | -1.2 | true | White | TRIAL-2023B | SITE-NY-109 | 2022-03-15 | 83 | male | drug B | 2022-03-15 | BP:138/86, Wt:78kg, LDL:99 | 13 | 2022-10-15 | completed | 2022-10-15 | 4 | blank | blank |
| PT-TRIAL3-031 | unchanged | 0.6 | false | Other | TRIAL-2023D | SITE-CA-227 | 2022-02-10 | 63 | other | drug A | 2022-02-12 | BP:129/79, Wt:85kg, Glu:101 | 11 | 2022-08-10 | completed | 2022-08-10 | 2 | blank | blank |
| P-TRIAL5-017 | worsened | -2.3 | true | White | TRIAL-2024B | SITE-FL-613 | 2022-04-15 | 73 | female | placebo | 2022-04-16 | BP:142/95, Wt:90kg, LDL:122 | 10 | 2022-10-15 | completed | 2022-10-15 | 3 | blank | blank |
| PT-TR2-VT-07 | unchanged | 0.4 | false | Asian | TRIAL-2023D | SITE-VT-912 | 2022-05-01 | 52 | male | drug A | 2022-05-03 | BP:119/72, Wt:66kg, HbA1c:5.6 | 8 | 2022-11-20 | completed | 2022-11-20 | 1 | blank | blank |
| PT-TRIAL4-017 | improved | 1.1 | false | Native Hawaiian/Pacific Islander | TRIAL-2024B | SITE-TX-418 | 2022-06-28 | 29 | female | drug B | 2022-06-29 | BP:118/74, Wt:55kg, Chol:152 | 6 | 2022-12-28 | completed | 2022-12-28 | 1 | blank | blank |
What the 203 rows show
from the 203-row sampleWorsened (outcome summary) stands out: 23 of its 25 rows have serious_
- 17%serious_
adverse_ event = true - 1.6median primary_
outcome_ value - 4sexes
- 4treatment groups
- 4progress statuses
- 25trials
Median 1.6, from -3.2 to 4.8.
- string 10
- integer 3
- float 1
- date 5
- boolean 1
Columns
20 columns in four groups| column | type | description | example |
|---|---|---|---|
| Text 10 columns | |||
patient_id | string | Unique identifier for each clinical trial subjectunique | PT-TRIAL1-001 |
trial_id | string | Identifier for the clinical trial in which the patient is enrolled | TRIAL-2023A |
site_id | string | Identifier for the clinical trial site where the patient is enrolledoptional | SITE-NY-101 |
sex | string | Biological sex of the patientmale · female · other · unknown | female |
race_ethnicity | string | Self-reported race or ethnicity of the patient11 ethnicities · optional | White |
treatment_group | string | Assigned treatment group (e.g., placebo, drug A, drug B)4 groups | drug A |
baseline_measurements | string | Key baseline clinical measurements (e.g., blood pressure, weight, lab values) at enrollmentoptional | BP:132/86, Wt:73.5 |
progress_status | string | Current status of patient in the trial (e.g., ongoing, completed, withdrawn, lost to follow-up)5 values | completed |
outcome_summary | string | Text summary or code for the overall outcome (e.g., improved, unchanged, worsened, not evaluable)4 summaries · optional | improved |
withdrawal_reason | string | Reason for withdrawal if patient did not complete the trialoptional | Extreme age exclusion |
| Numbers 4 columns | |||
age | integer | Age of the patient at enrollment (in years)0 to 120 | 42 |
visit_number | integer | Current or last completed visit number in the study protocol1 or more · optional | 7 |
primary_outcome_value | float | Measured value for the primary outcome (if applicable)optional | 2.3 |
adverse_events_reported | integer | Number of adverse events reported for this patient0 or more · optional | 1 |
| Dates and times 5 columns | |||
enrollment_date | date | Date when the patient was enrolled in the trial | 2022-01-12 |
randomization_date | date | Date when the patient was randomized to a treatment groupoptional | 2022-01-13 |
last_visit_date | date | Date of the most recent completed study visitoptional | 2022-07-19 |
primary_outcome_date | date | Date when the primary outcome was assessedoptional | 2022-07-19 |
death_date | date | Date of death if applicableoptional | 2022-08-18 |
| True or false 1 column | |||
serious_adverse_event | boolean | Indicates if the patient experienced any serious adverse event during the trialoptional | false |
Use it for
A healthcare dashboard
The serious_
adverse_ event rate, primary_ outcome_ value by outcome_ summary and a breakdown of race_ ethnicity. Excel, Power BI or Tableau. Why do 34 of 203 rows have serious_
adverse_ event = true? A root-cause class exercise
Hand out the rows and one question. The answer is in the data, not in the brief.
- Patients203PT-TRIAL1-0012.3improvedP-TRIAL2-021-0.6worsenedPT-TRIAL2-101-1.2worsened
A software demo
Believable patients with trial_
id, site_ id and enrollment_ date to fill a screen in front of a buyer.
This dataset203 rows20 columns
Yours1,000 rows20 columnssite_id: UK only
blueprint · clinical-trial-patient-records
Behind this dataset
Same schema. As many rows as you need.
These 203 rows came out of a blueprint — 20 columns with generation rules behind each one. Open it in Data Factory to retune a column, add your own, wire in foreign keys, and run it at the size you actually need.
Rules it was built with
- Each record includes treatment assignment and milestones
- Outcome metrics: efficacy, side effects
- Randomized group assignment
- No real patient data
Open the blueprint in Data Factory
1 credit per row. Preview 20 rows free. Buy rows for the full run.
- Exports
- CSV, JSON, JSONL, Parquet, SQL, Excel, TSV, XML
- Licence
- yours to use, including commercially
- API slug
- clinical-trial-patient-records